Company description

CRBP, or Corbus Pharmaceuticals Holdings, Inc., is a clinical-stage biopharmaceutical company that focuses on developing and commercializing treatments for inflammatory and fibrotic diseases. The company was founded in 2009 and is based in Norwood, Massachusetts. CRBP utilizes its expertise in developing therapies that target the endocannabinoid system, a key regulator of inflammatory and fibrotic processes. By targeting this system, CRBP aims to provide patients with safe and effective treatments for a wide range of diseases, including cystic fibrosis, systemic sclerosis, and dermatomyositis, among others. The company's lead product candidate, lenabasum, is currently in several phase III clinical trials, with the potential to address unmet medical needs in chronic inflammatory and fibrotic diseases. CRBP is dedicated to helping patients with these debilitating conditions and is committed to advancing innovative therapies that can make a significant impact in the lives of those suffering from them.